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LETTER TO THE EDITOR
Nurse-like cells impact on disease progression in chronic
lymphocytic leukemia
Blood Cancer Journal (2016) 6, e381; doi:10.1038/bcj.2015.108;
published online 15 January 2016
Chronic lymphocytic leukemia (CLL) is one of the most common
B-cell malignancies in adults, characterized by an accumulation of
monoclonal CD5+ mature B cells in lymphoid tissues and
peripheral blood.1 The complex interplay between malignant
CLL cells and their surrounding bystander tumor microenviron-
ment (TME)2 is critical for their survival and facilitates both their
resistance to drug therapy and their orchestration of an
immunosubversive milieu.3 CLL cells proliferate in distinct
microanatomical tissue sites, termed proliferation centers,
that allow intimate interactions with TME components notably
nurse-like cells (NLC).4 These cells represent a leukemia-associated
counterpart of tissue-associated macrophages, expressing high
level of CD68 and CD1635,6 and mediating chemoresistance
particularly to ibrutinib, dexamethasone and chlorambucil.7
Even if these cells was well studied by in vitro approaches, the
in vivo clinical impact of NLC outgrowth in the TME has not been
deﬁnitively addressed to date in CLL, as described for the tumor-
associated macrophages (TAMs) in solid tumors. If high TAM
inﬁltration has been associated with a worse outcome in several
solid cancers as well as in hematological malignancies including
diffuse large B-cell lymphoma,8 in CLL studies were focused on
indirect proof of evidence. Indeed, if CCL3 levels are associated
with shorter treatment-free survival (TFS)9 and HMGB1 expression
levels in the TME have been correlated with overall survival (OS),10
these prognostic factors do not clearly identify NLC inﬁltration as
an important parameter associated with CLL outcome.
In the present study, we demonstrated that TME, particularly
NLC, could impact CLL progression. For this purpose, we reported
for the ﬁrst time that (i) CD163+ NLC expression is correlated with
CLL proliferation in lymph nodes (LNs), (ii) high soluble CD163
(sCD163) levels, the soluble counterpart of CD163, are linked
with the worst prognostic factors in this disease, namely TP53
mutations, complex karyotype and unmutated immunoglobulin
heavy-chain variable (IGHV) status and (iii) high levels of sCD163
are associated with shorter TFS and OS.
To determine the clinical impact of NLC, we ﬁrst compared the
in vivo anatomical pattern of CD163+ macrophages in both
healthy donor (reactive tonsils, Figure 1a) and CLL LNs tissue
sections (Figure 1b). In normal LNs and tonsils, CD163+ macro-
phages were conﬁned to the sub-capsular areas and along the
lymphatic sinuses, whereas the B-cell zones were devoid of
CD163+ cells, as previously reported. Moreover, in CLL LNs,
CD163+ macrophages were present in the medulla, intertwined
with leukemic cells and pseudofollicles. Confocal microscopy
revealed that CD163+ cells were consistently CD68+ in CLL LNs,
while some CD68+ macrophages were devoid of CD163 expres-
sion (Supplementary Figure 1). Because CD68 can also be
expressed by non-myeloid cells,11 we hypothesized that CD68
staining might over-interpret the exact quantity of NLC in LNs and
we decided to use CD163 as the most relevant marker for NLC.
We next questioned the reliability of CD163+ NLC within TME
with regards to disease progression. We then performed
immunohistochemistry analyses on 27 previously untreated CLL
patients for whom nodal tissue biopsies were available in our
institution. These patients had either a suspicion of disease
transformation or were biopsied before CLL was evidenced from
the immunophenotyping of circulating lymphocytes. As shown in
Figures 1c and d, some patients (for example, patients 1 and 2)
had few Ki-67+ proliferating CLL cells within pseudofollicles (and
few CD163+ cells), and had indolent CLL. Notably, these watch and
wait patients still had more CD163+ macrophages intertwined
with tumoral B cells, as compared with normal LNs. In contrast,
patients with active CLL (as deﬁned by IWCLL2008 criteria)
requiring therapy presented with (i) an increased frequency and
size of pseudofollicles (for example, patients 3 and 4, Figures 1c
and d), (ii) a higher fraction of Ki-67+ CLL cells and (iii) a
signiﬁcantly higher number of CD163+ cells. This is particularly
relevant in the proliferating centers, as indolent CLL had very few
CD163+ cells in these areas. Altogether, these data from a large
cohort of 27 patients suggested that CD163+ cells load within the
TME was signiﬁcantly higher as CLL progressed towards ﬁrst line
of treatment.
In previous studies, sCD163 may be used as a reliable marker of
the total pool of CD163+ cells in various conditions.12 Because of
the limited availability of LN biopsies, and the absence of CD163
expression by circulating monocytes in CLL patients,6 we
evaluated sCD163 levels (in serum) and other related soluble
factor such as soluble CD68 (sCD68) and soluble HGMB1
(sHMGB1). Indeed, we found a higher amounts of sCD163,
sCD68 and sHMGB1 in the sera of CLL patients than in
age-matched normal donor sera (Figure 1e). Then, in this cohort
of 94 patients naive to therapy (for thorough analysis of patient
characteristics, see Supplementary Table 1), we correlated soluble
factors levels with previously established prognostic markers.
We found a statistically signiﬁcant association between high sera
levels of sCD163 and poor prognostic markers, such as unmutated
IGHV status, complex karyotypes (deﬁned by 43 anomalies), the
presence of TP53 mutations and a trend towards an association
with del(17p) and NOTCH1 mutational status (P= 0.055; Table 1).
This was very relevant as these markers are considered as the
worst prognostic markers in this disease. On the other hand,
we found no such correlation with Binet stage, suggesting
aggressiveness of disease reﬂected more faithfully than ‘crude
accumulation’ of leukemic cells within tissues, and the amount of
CD163+ macrophages in these patients (Supplementary Figure 2).
We did not ﬁnd any evidence of association between sCD68 or
sHMGB1 levels and CLL prognostic factors (Table 1). Lymphocy-
tosis (that is, circulating tumor bulk) or monocytosis (that is,
putative precursors of NLCs once recruited to tumor niches) also
had no impact on the levels of the three soluble factors studied
(Supplementary Figure 2). Altogether, as sCD163 levels did not
correlate with sCD68/HMGB1 levels (Supplementary Figure 2), our
data suggest for the ﬁrst time that aggressive CLL modulate their
TME to increase the education of monocytes into CD163+ cells.
Of the 94 patients included in our study, 78 required treatment,
according to the IWCLL2008 criteria for active disease, and 24 died
during follow-up. Median time to ﬁrst treatment in the entire cohort
was short (36 months; Supplementary Tables 2 and 3). By receiver
operating characteristic analysis we found that 1000 ng/ml of
sCD163 was the best threshold to segregate patients into two
Citation: Blood Cancer Journal (2016) 6, e381; doi:10.1038/bcj.2015.108
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groups. sCD163high patients had signiﬁcantly shorter TFS (logrank
P=0.04, 30 versus 42 months; Figure 1f, Supplementary Table 2b),
but also shorter OS (logrank P=0.03; Figure 1g, Supplementary
Table 3). These last data are important, as most patients requiring
therapy received modern immune-chemotherapy regimens
(Supplementary Table 2b). On the other hand, sCD68 (high if
421 ng/ml) and sHMGB1 (high if4227 ng/ml) were not associated
with outcomes (Supplementary Figures 2 and 3). Interestingly, this
increase of sCD163 levels in patient sera can be found in other
hemopathy including Hodgkin lymphoma,13 a previous publication
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(though exploring a smaller CLL cohort) showed very similar levels
as ours, both in CLL patients or healthy donor (suggesting we are
not studying a too-selected panel of samples).14 In the former
study, using a higher threshold (2.45 mg/l) to predict only TFS (not
OS), the authors pointed towards a role of CD163 without functional
data with NLC, as we present in this manuscript.14 Furthermore in
our cohort, high levels of sCD163 are linked to well-established
adverse biological factors, such as IGHV mutational status as
previously described,14 but also the presence of TP53 mutations
and complex karyotype, suggesting that leukemic cells with high-
risk features raise more CD163+ cells within their TME, an as yet
unanswered question in the ﬁeld of TAMs in oncology. In univariate
analyses, sCD163 levels predicted TFS with SF3B1mutated status,
normal ﬂuorescence in situ hybridization and Binet stage
(Supplementary Table 2). In univariate analyses for OS, sCD163,
deletion of chromosome 17p and TP53 mutated status were
predictive (Supplementary Table 3). Altogether, our data suggest
that, being associated with TP53 mutations, IGHV unmutated status
and complex karyotypes, sCD163 is TME-related risk factor
associated with shorter survival after frontline immunochemother-
apy, and therefore should be investigated in independent cohorts
of patients. Even if the size of the cohort precludes from drawing
too strong statements in terms of OS particularly, these deaths were
all CLL related. sCD163 has been indeed related to survival in a wide
variety of medical conditions, outside the cancer setting. Moreover,
despite we conﬁrmed the increased sHMGB1 levels published by
Table 1. Correlation between levels of sCD163, sCD68 or sHMGB1 and established prognostic markers in CLL
Characteristics Category Median sCD163
(range)
P-value
(CD163)
Median sCD68
(range)
P-value
(CD68)
Median sHMGB1
(range)
P-value
(HMGB1)
Age o65 years 887.4
(326.4–2312)
26.54
(10.1–26.5)
192.3
(167.3–390.7)
465 years 985
(302–4944)
0.6619 28.14
(11.6–124.6)
0.1918 190.7
(160.7–274.0)
0.482
Sex Female 686
(375.2–3427)
28.30
(15.9–73.5)
190.7
(160.7–274.0)
Male 1098
(235–4944)
0.2586 26.16
(10.1–124.6)
0.3106 190.7
(167.3–390.7)
0.4563
IGHV status Mutated 669
(302–4944)
22.3
(11.6–124.6)
190.7
(160.7–274)
Unmutated 1308
(235-2662)
0.0031 28.1
(12.7–73.5)
0.3858 194
(167.3–390.7)
0.5336
Cytogenetics Tri 12 1227
(376–1558)
0.1152 25.2
(12.7–28.4)
0.8279 180.7
(174.0–197.3)
0.2823
Del(13q) 946
(375.2–2359)
0.7053 30.4
(15.9–68.9)
0.1632 190.7
(174.0–214.0)
0.9749
Del(11q) 597
(565–4944)
0.6617 31.1
(15.9–52.9)
0.5963 200.7
(174–390.7)
0.4194
Del(17p) 1775
(995-1922)
0.0743 17.5
(15.5–19.4)
0.2142 187.3
(184.0–190.7)
0.4897
Complex
karyotype
184
5 (1162–1922)
0.0236 18.4
(15.5–19.4)
0.0799 189.0
(184.0–190.7)
0.1658
Recurrent
mutations
SF3B1 1308
(621.1–2298)
0.2611 32.3
(18.2–68.9)
0.5839 185.7
(167.3–204.0)
0.3607
NOTCH1 1562
(416–4944)
0.0555 32.8
(12.7–52.9)
0.1399 197.3
(184.0–254.0)
0.0718
TP53 1764
(995–4944)
0.0093 35.1
(15.5–80.0)
0.4309 190.7
(180.7–204.0)
0.9766
Abbreviations: Del, deletion; IGHV, immunoglobulin heavy-chain variable segment mutational status; tri 12, trisomy 12. In our series, high sCD163 levels were
found to be correlated with TP53mutational status, unmutated IGHV and complex karyotypes, the three most predictive variables for survival (progression-free
survival and OS) in CLL. A trend towards signiﬁcance was also seen with del(17p) and NOTCH1 mutations, suggesting that these CLL cases modulate their TME
towards an increase in CD163+ cells.
Figure 1. High soluble CD163 levels correlate with shorter treatment-free survival (TFS) and shorter overall survival (OS). (a) CD163+ staining
from one representative (n= 7) healthy donor lymph node tissue section. CD163+ cells were present in the lymphatic sinuses and along the
sub-capsular area, but were excluded from the germinal center remnants (pink) in the normal lymph node (×200). (b) CD163+ staining from
one representative (n= 27) CLL lymph node tissue section. CD163+ cells (brown) were spread throughout the parenchyma, inﬁltrating
proliferation centers (pink) in the CLL lymph node (×200). CD163+ cells were stained with a CD163 antibody (brown) and germinal center
cells/proliferating CLL cells with a Ki-67 antibody (pink). (c) Representative pictures showing the density and distribution of CD163+ in CLL LN
from two patients with indolent CLL (Pt #1 and #2), and two patients with therapy-urging CLL (Pt#3 and #4; × 100). (d) According to disease
aggressiveness, the number of CD163+ cells both outside and within proliferating centers signiﬁcantly differs, suggesting that the number of
NLCs within the TME may be used for prognostication purposes. NLCs were stained with a CD163 antibody (brown) and proliferation centers
with a Ki-67 antibody (pink). Relative quantiﬁcation of Ki-67+ cells or CD163+ cells was made by two-blinded separate analyses.
(e) Quantiﬁcation (by enzyme-linked immunosorbent assay testing) of soluble CD163 (left), soluble CD68 (center) or soluble HMGB1 (right) in
serum from healthy donors (K) or CLL patients (’) shows a signiﬁcant increase of all three markers only in CLL patients (mirroring NLCs–CLL
interactions in the TME). Soluble HMGB1 levels show very few disparities among patient samples, whereas s.d.’s of the CD163 and CD68
dosages are broader. (f, g) Kaplan–Meier curves showing the probability of (f) TFS and (g) OS. CLL patients were divided into groups of
patients with low (o1000 ng/ml, gray curve) or high (41000 ng/ml, black curve) levels of sCD163. These categories were determined by
receiver operating characteristic curves. *Po0.05, **Po0.01, ***Po0.001.
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Jia et al.10 in CLL sera, in our cohort sHMGB1 or sCD68 levels cannot
be linked to prognostic markers or outcome. These results reinforce
the prominence of CD163 or its soluble counterpart to determine in
future studies the burden and clinical impact of NLC in disease
course in a large cohort of LNs or sera, as previously published in
myeloma.15
In summary, we have demonstrated for the ﬁrst time that
CD163 and its soluble counterpart sCD163 are the best markers for
future studying of NLC in vivo and in vitro. If future studies are
needed to deﬁnitely identify CD163+ NLC (or sCD163) as the ﬁrst
TME-related prognostic factor having clinical impact in CLL,
targeting therapies against these cells are promising approaches
to overcome TME pro-survival capacities in CLL.
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